Legislation Archives - Dehoney Financial Group Ltd.

Patented Medicines Regulations: UPDATE July 13, 2020

As reported by Kelsey Rolfe of Benefits Canada, reforms to the Patented Medicines Pricing Review Board (PMPRB) have been upheld by the Federal Court. This decision followed an application for judicial review by Innovative Medicines Canada and 16 pharmaceutical companies who opposed the amendments which included:

In setting drug prices, a “basket” of 11 other countries (no longer including the US and Switzerland), that are similar to Canada’s population, economy and approach to health care, will be used to compare prices.
In establishing a price ceiling for a drug in Canada, the PMPRB will now have access […]

Changes to OHIP+ Effective April 1, 2019

Patented Medicines Regulations

Recently, the Government of Ontario and insurer Industrial Alliance (IA) prepared some helpful information related to the upcoming changes to OHIP+. Our team assembled those details below to help our clients and plan administrators manage the transition.

APRIL 1, 2019 OHIP+ WILL NO LONGER COVER INDIVIDUALS 24 YEARS OLD AND UNDER WITH DRUG COVERAGE THROUGH A PRIVATE INSURANCE PLAN.

This is a major change to OHIP+ which impacts all youth aged 24 years and under covered by a private group insurance plan. Effective April 1, 2019 prescription drug claims must be submitted to a […]

Will modernizing the Patented Medicines Regulations in Canada lead to savings?

Patented Medicines Regulations

The Patented Medicines Regulations, those rules that govern the pricing of pharmaceuticals in Canada, are about to change. Many would suggest that it’s about time. There have been no substantive changes in over 20 years and Canada pays some of the highest drug prices when compared to countries of the Organisation for Economic Co-operation and Development (OECD). The United States and Mexico are the only two OECD countries that have higher patented drug prices than Canada.

The government’s proposal, titled Protecting Canadians from Excessive Drug Prices, sets out amendments to the current drug pricing regulations and may […]